A Phase 1 study of MT-401-OTS in AML and MDS

Recruiting Phase 1 NCT06552416

Study Description

A Study to Evaluate the Safety and Efficacy of MT-401-OTS in Patients with Relapsed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Study Details

Registry ID:: NCT06552416
Conditions:: Acute Myeloid Leukemia, in Relapse, MDS
Phase:: Phase 1
Target Enrollment:: 40 participants
Start Date:: June 16, 2025
Age Range:: 65–999 years
Healthy Volunteers:: No

Study Locations (3 sites)

Moffitt Cancer Center
Tampa, FloridaUnited States, United States
KU Cancer Center
KAnsas city, KansasUnited States, United States
City of Hope Center (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →